UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 457

Sortiert nach

Variants in the SLCO1B3 Gene: Interethnic Distribution and Association with Paclitaxel Pharmacokinetics

Clinical pharmacology and therapeutics, 2007-01, Vol.81 (1), p.76-82

2007

Volltextzugriff (PDF)

Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750—an antisense oligonucleotide against eIF4E—in combination with irinotecan in solid tumors and irinotecan‐refractory colorectal cancer

International journal of cancer, 2016-10, Vol.139 (7), p.1648-1657

2016

Volltextzugriff (PDF)

The CYP2C1917 variant is not independently associated with clopidogrel response

Journal of thrombosis and haemostasis, 2013-09, Vol.11 (9), p.1640-1646

2013

Volltextzugriff (PDF)

Effect of ABCC2 (MRP2) Transport Function on Erythromycin Metabolism

Clinical pharmacology and therapeutics, 2011-05, Vol.89 (5), p.693-701

2011

Volltextzugriff (PDF)

A Randomized Phase II Trial of Thalidomide, an Angiogenesis Inhibitor, in Patients with Androgen-independent Prostate Cancer

Clinical cancer research, 2001-07, Vol.7 (7), p.1888-1893

2001

Volltextzugriff (PDF)

A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform

The pharmacogenomics journal, 2010-06, Vol.10 (3), p.191-199

2010

Volltextzugriff (PDF)

Phase II Trial of the Antiangiogenic Agent Thalidomide in Patients With Recurrent High-Grade Gliomas

Journal of clinical oncology, 2000-02, Vol.18 (4), p.708-715

2000

Volltextzugriff (PDF)

Angiogenesis in Spontaneous Tumors and Implications for Comparative Tumor Biology

TheScientificWorld, 2014-01, Vol.2014, p.919570-16

2014

Volltextzugriff (PDF)

OATP1B1 Polymorphism as a Determinant of Erythromycin Disposition

Clinical pharmacology and therapeutics, 2012-11, Vol.92 (5), p.642-650

2012

Volltextzugriff (PDF)

Inhibition of Angiogenesis by Thalidomide Requires Metabolic Activation, Which Is Species-dependent

Biochemical pharmacology, 1998-06, Vol.55 (11), p.1827-1834

1998

Volltextzugriff (PDF)

Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group

Journal of clinical oncology, 1999-11, Vol.17 (11), p.3461-3467

1999

Volltextzugriff (PDF)

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms

Journal of clinical oncology, 1998-09, Vol.16 (9), p.2986-2999

1998

Volltextzugriff (PDF)

The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy

Leukemia, 2001-10, Vol.15 (10), p.1537-1543

2001

Volltextzugriff (PDF)

Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory Neoplasms

Journal of clinical oncology, 2001-04, Vol.19 (8), p.2319-2333

2001

Volltextzugriff (PDF)

Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100

British journal of cancer, 2008-05, Vol.98 (10), p.1630-1632

2008

Volltextzugriff (PDF)

The Pharm.D. Investigator in Clinical Pharmacology: Supply and Demand

Clinical pharmacology and therapeutics, 2008-10, Vol.84 (4), p.526-529

Figg, WD

2008

Volltextzugriff (PDF)

Contribution of the OATP1B Subfamily to Cancer Biology and Treatment

Clinical pharmacology and therapeutics, 2012-11, Vol.92 (5), p.658-660

2012

Volltextzugriff (PDF)

Activity of Thalidomide in AIDS-Related Kaposi’s Sarcoma

Journal of clinical oncology, 2000-07, Vol.18 (13), p.2593-2602

2000

Volltextzugriff (PDF)

Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer

Clinical cancer research, 1996-03, Vol.2 (3), p.483-491

1996

Volltextzugriff (PDF)

Thalidomide neuropathy in patients treated for metastatic prostate cancer

Muscle & nerve, 2001-08, Vol.24 (8), p.1050-1057

2001

Volltextzugriff (PDF)

Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs

Leukemia, 2005-07, Vol.19 (7), p.1253-1261

2005

Volltextzugriff (PDF)

A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib

United European gastroenterology journal, 2015-10, Vol.3 (5), p.453-461

2015

Volltextzugriff (PDF)

Phase I Clinical Trial of Oral COL-3, a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer

Journal of clinical oncology, 2001-01, Vol.19 (2), p.584-592

2001

Volltextzugriff (PDF)

Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma

Journal of clinical oncology, 1998-03, Vol.16 (3), p.1112-1121

1998

Volltextzugriff (PDF)

TNP-470: an angiogenesis inhibitor in clinical development for cancer

Expert opinion on investigational drugs, 2000-06, Vol.9 (6), p.1383-1396

2000

Volltextzugriff (PDF)

1 – 25 von 457

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(435)
Mit Volltextzugriff
(404)

Publikationsform

Sprache

Englisch
(457)
Japanisch
(52)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Variants in the SLCO1B3 Gene: Interethnic Distribution and Association with Paclitaxel Pharmacokinetics

Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750—an antisense oligonucleotide against eIF4E—in combination with irinotecan in solid tumors and irinotecan‐refractory colorectal cancer

The CYP2C1917 variant is not independently associated with clopidogrel response

Effect of ABCC2 (MRP2) Transport Function on Erythromycin Metabolism

A Randomized Phase II Trial of Thalidomide, an Angiogenesis Inhibitor, in Patients with Androgen-independent Prostate Cancer

A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform

Phase II Trial of the Antiangiogenic Agent Thalidomide in Patients With Recurrent High-Grade Gliomas

Angiogenesis in Spontaneous Tumors and Implications for Comparative Tumor Biology

OATP1B1 Polymorphism as a Determinant of Erythromycin Disposition

Inhibition of Angiogenesis by Thalidomide Requires Metabolic Activation, Which Is Species-dependent

Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms

The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy

Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory Neoplasms

Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100

The Pharm.D. Investigator in Clinical Pharmacology: Supply and Demand

Contribution of the OATP1B Subfamily to Cancer Biology and Treatment

Activity of Thalidomide in AIDS-Related Kaposi’s Sarcoma

Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer

Thalidomide neuropathy in patients treated for metastatic prostate cancer

Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs

A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib

Phase I Clinical Trial of Oral COL-3, a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer

Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma

TNP-470: an angiogenesis inhibitor in clinical development for cancer

Suchergebnisse filtern